secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0000950170-25-017915
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M
--------------------------------------------------------------------------------

- Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).
- clonoSEQ test volume Q4 20,945 tests (+34% YoY); full year 76,105 tests (+35%).
- Net loss Q4 $33.7M vs $69.5M a year ago; FY net loss $159.6M vs $225.3M. Adjusted EBITDA loss Q4 $16.4M vs $24.7M.
- FY2025 guidance: MRD revenue $175-185M; total operating expenses $340-350M; cash burn $60-70M.
- FDA ODAC unanimously voted to support MRD as primary endpoint for accelerated approval in multiple myeloma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/0000950170-25-017915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/adpt-20250211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-017915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer